The Next Generation Biomanufacturing Market was valued at USD 31.87 Billion in 2023 and USD 36.69 Billion in 2024. The market is projected to reach USD 113.27 Billion by 2032, registering a CAGR of 15.13% during the forecast period. Market development is being driven by increasing R&D investment, growing demand for personalized medicines, expanding adoption of biologics, advancements in cell and gene therapies, increasing automation, digitalization, and the need for more efficient and sustainable manufacturing processes.
Next-generation biomanufacturing encompasses advanced technologies and manufacturing approaches designed to improve the efficiency, flexibility, scalability, and quality of biopharmaceutical production. These approaches include advanced bioreactors, continuous processing, automation, artificial intelligence, robotics, process analytical technologies, and other digital manufacturing systems.
The growing adoption of biologics is creating substantial demand for advanced manufacturing technologies. Complex biological products require sophisticated production systems capable of maintaining quality and consistency at commercial scale.
Cell and gene therapies are also increasing the need for flexible and technologically advanced manufacturing infrastructure. These therapies require specialized production capabilities, while personalized medicine is creating demand for manufacturing systems capable of supporting smaller and more individualized production requirements.
Automation and AI integration are transforming biomanufacturing by enabling real-time monitoring, predictive analytics, process optimization, and automated control. These technologies can improve productivity, reduce operating costs, and support consistent product quality.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.wiseguyreports.com/reports/next-generation-biomanufacturing-market
Key Companies in the Global Next Generation Biomanufacturing Market
Fujifilm
Becton, Dickinson and Company
WuXi Biologics
Mitsubishi Chemical
Catalent
Charles River Laboratories
Merck KGaA
Sartorius Group
Thermo Fisher Scientific
Lonza Group
MilliporeSigma
Cytiva
Novo Nordisk
Samsung Biologics
Danaher
GE Healthcare
Market Dynamics and Growth Drivers
Growing demand for personalized medicine is a major driver of next-generation biomanufacturing. Personalized therapies require flexible manufacturing systems capable of producing complex and potentially smaller-volume therapeutic products.
The growing adoption of biologics is another important factor. Biologics are increasingly used across oncology, autoimmune diseases, inflammatory disorders, and other therapeutic areas, creating demand for advanced production technologies.
Advancements in cell and gene therapy are also expanding market opportunities. These therapies require specialized manufacturing systems, increasing demand for advanced bioprocessing equipment and automated production technologies.
Single-use bioreactors are becoming increasingly important because of their flexibility, scalability, and reduced contamination risks. Perfusion, fed-batch, and wave bioreactor technologies are also supporting different production requirements.
Automation, robotics, and artificial intelligence are improving process monitoring and control. Process Analytical Technology can provide real-time information about manufacturing conditions, while AI-driven analytics can help predict outcomes and optimize processes.
Regional Market Insights
North America held the largest share of the global market in 2023, accounting for more than 35% of global revenue in 2024 according to the report’s regional analysis. The presence of major pharmaceutical and biotechnology companies, favorable policies, and high R&D investment supports regional development.
Europe represents another important market, supported by strong pharmaceutical manufacturing capabilities, biotechnology research, and increasing adoption of advanced manufacturing technologies.
Asia Pacific is expected to experience significant growth, with the report identifying increasing demand for biopharmaceuticals, rising healthcare expenditure, and supportive government policies as major regional drivers. China and India are important markets within the region.
South America and the Middle East and Africa are also expected to experience growth as pharmaceutical infrastructure develops and investment in biotechnology and biomanufacturing increases.
Market Segmentation
By Therapeutic Product Type, the market includes Recombinant Proteins, Monoclonal Antibodies, Gene Therapies, and Cell-Based Therapies. Recombinant Proteins were valued at approximately USD 26.69 Billion in 2024 and are projected to reach USD 63.27 Billion by 2032. Monoclonal Antibodies represented another significant product category.
By Target Disease, the market is segmented into Cancer, Cardiovascular Disease, Neurological Disorders, and Infectious Diseases. Cancer represented the largest target-disease segment, accounting for more than 50% of the market in 2023.
By Bioreactor Technology, the market includes Single-Use Bioreactors, Perfusion Bioreactors, Fed-Batch Bioreactors, and Wave Bioreactors. Single-Use Bioreactors accounted for more than 45% of market revenue in 2024, supported by their flexibility, scalability, and reduced contamination risks.
By Automation and Control, the market includes Process Analytical Technology, Bioprocess Control Systems, Robotics, and Artificial Intelligence. These technologies support real-time monitoring, process optimization, automation, and improved manufacturing productivity.
By Artificial Intelligence Integration, the market includes Machine Learning, AI-driven Process Optimization, AI-based Predictive Analytics, and AI-powered Process Automation. The AI integration segment is expected to reach approximately USD 11.23 Billion by 2027, registering a CAGR of 18.5%.
Recent Developments and Market Trends:
Growing demand for personalized medicines is increasing the need for flexible biomanufacturing systems.
Biologics adoption is expanding demand for advanced manufacturing infrastructure.
Cell and gene therapy development is creating new manufacturing requirements.
Single-use bioreactors are gaining adoption because of flexibility and reduced contamination risks.
Automation and digitalization are improving process control and manufacturing efficiency.
AI-based predictive analytics and process optimization are expanding within biomanufacturing.
Pfizer and Moderna announced plans to invest in next-generation mRNA manufacturing facilities.
Merck KGaA acquired Arvinas to expand its targeted protein degradation capabilities.
Gilead Sciences partnered with Catalent to establish a dedicated manufacturing facility for cell and gene therapies.
Reasons to Buy the Report:
Understand the next-generation biomanufacturing market size and forecast.
Analyze therapeutic product, disease, bioreactor, automation, AI, and regional segments.
Identify major factors driving advanced biomanufacturing adoption.
Review the role of single-use, perfusion, fed-batch, and wave bioreactors.
Understand AI-driven process optimization and predictive analytics opportunities.
Analyze growth opportunities created by personalized medicine and advanced therapies.
Evaluate major companies and recent developments in the biomanufacturing industry.
Future Outlook:
The Next Generation Biomanufacturing Market is expected to experience strong expansion as pharmaceutical and biotechnology companies increase investments in advanced production technologies for biologics, personalized medicines, cell therapies, gene therapies, and other complex products. Continued development of single-use bioreactors, continuous processing, automation, robotics, process analytical technologies, artificial intelligence, and predictive analytics is expected to improve manufacturing efficiency and scalability. Increasing demand for flexible and sustainable production systems is expected to create additional opportunities across pharmaceutical manufacturing and contract manufacturing organizations through the forecast period.
➤➤Explore Our Latest Related Reports:
